Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Human Cytomegalovirus Genomes Sequenced Directly from Clinical Material: Variation, Multiple-Strain Infection, Recombination and Gene Loss.

Suárez NM, Wilkie GS, Hage E, Camiolo S, Holton M, Hughes J, Maabar MD, Sreenu VB, Dhingra A, Gompels UA, Wilkinson GWG, Baldanti F, Furione M, Lilleri D, Arossa A, Ganzenmueller T, Gerna G, Hubáček P, Schulz TF, Wolf D, Zavattoni M, Davison AJ.

J Infect Dis. 2019 May 2. pii: jiz208. doi: 10.1093/infdis/jiz208. [Epub ahead of print]

PMID:
31050742
2.

High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.

Nightingale K, Lin KM, Ravenhill BJ, Davies C, Nobre L, Fielding CA, Ruckova E, Fletcher-Etherington A, Soday L, Nichols H, Sugrue D, Wang ECY, Moreno P, Umrania Y, Huttlin EL, Antrobus R, Davison AJ, Wilkinson GWG, Stanton RJ, Tomasec P, Weekes MP.

Cell Host Microbe. 2018 Sep 12;24(3):447-460.e11. doi: 10.1016/j.chom.2018.07.011. Epub 2018 Aug 16.

3.

Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses.

Wang ECY, Pjechova M, Nightingale K, Vlahava VM, Patel M, Ruckova E, Forbes SK, Nobre L, Antrobus R, Roberts D, Fielding CA, Seirafian S, Davies J, Murrell I, Lau B, Wilkie GS, Suárez NM, Stanton RJ, Vojtesek B, Davison A, Lehner PJ, Weekes MP, Wilkinson GWG, Tomasec P.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):4998-5003. doi: 10.1073/pnas.1720950115. Epub 2018 Apr 24.

4.

No Equity, No Triple Aim: Strategic Proposals to Advance Health Equity in a Volatile Policy Environment.

Wilkinson GW, Sager A, Selig S, Antonelli R, Morton S, Hirsch G, Lee CR, Ortiz A, Fox D, Lupi MV, Acuff C, Wachman M.

Am J Public Health. 2017 Dec;107(S3):S223-S228. doi: 10.2105/AJPH.2017.304000.

5.

The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.

Murrell I, Bedford C, Ladell K, Miners KL, Price DA, Tomasec P, Wilkinson GWG, Stanton RJ.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6104-6109. doi: 10.1073/pnas.1704809114. Epub 2017 May 22.

6.

Genomic analysis of chimeric human cytomegalovirus vaccine candidates derived from strains Towne and Toledo.

Suárez NM, Lau B, Kemble GM, Lee R, Mocarski ES, Wilkinson GWG, Adler SP, McVoy MA, Davison AJ.

Virus Genes. 2017 Aug;53(4):650-655. doi: 10.1007/s11262-017-1452-0. Epub 2017 Apr 8.

7.

Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation.

Fielding CA, Weekes MP, Nobre LV, Ruckova E, Wilkie GS, Paulo JA, Chang C, Suárez NM, Davies JA, Antrobus R, Stanton RJ, Aicheler RJ, Nichols H, Vojtesek B, Trowsdale J, Davison AJ, Gygi SP, Tomasec P, Lehner PJ, Wilkinson GW.

Elife. 2017 Feb 10;6. pii: e22206. doi: 10.7554/eLife.22206.

8.

Genetic Stability of Bacterial Artificial Chromosome-Derived Human Cytomegalovirus during Culture In Vitro.

Murrell I, Wilkie GS, Davison AJ, Statkute E, Fielding CA, Tomasec P, Wilkinson GW, Stanton RJ.

J Virol. 2016 Mar 28;90(8):3929-43. doi: 10.1128/JVI.02858-15. Print 2016 Apr.

9.

Community Health Worker Integration in Health Care, Public Health, and Policy: A Partnership Model.

Wilkinson GW, Mason T, Hirsch G, Calista JL, Holt L, Toledo J, Zotter J.

J Ambul Care Manage. 2016 Jan-Mar;39(1):2-11.

PMID:
26650741
10.

[Adenoviral Vectors in Gene Therapy].

Pjechová M, Hernychová L, Tomašec P, Wilkinson GW, Vojtěšek B.

Klin Onkol. 2015;28 Suppl 2:2S75-80. Review. Czech.

PMID:
26374162
11.

Human cytomegalovirus: taking the strain.

Wilkinson GW, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, Seirafian S, Wang EC, Weekes M, Lehner PJ, Wilkie GS, Stanton RJ.

Med Microbiol Immunol. 2015 Jun;204(3):273-84. doi: 10.1007/s00430-015-0411-4. Epub 2015 Apr 17. Review.

12.

Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.

Hsu JL, van den Boomen DJ, Tomasec P, Weekes MP, Antrobus R, Stanton RJ, Ruckova E, Sugrue D, Wilkie GS, Davison AJ, Wilkinson GW, Lehner PJ.

PLoS Pathog. 2015 Apr 14;11(4):e1004811. doi: 10.1371/journal.ppat.1004811. eCollection 2015 Apr.

13.

CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue.

Stack G, Jones E, Marsden M, Stacey MA, Snelgrove RJ, Lacaze P, Jacques LC, Cuff SM, Stanton RJ, Gallimore AM, Hussell T, Wilkinson GW, Ghazal P, Taylor PR, Humphreys IR.

PLoS Pathog. 2015 Feb 5;11(2):e1004641. doi: 10.1371/journal.ppat.1004641. eCollection 2015 Feb.

14.

Abrogation of the interferon response promotes more efficient human cytomegalovirus replication.

McSharry BP, Forbes SK, Avdic S, Randall RE, Wilkinson GW, Abendroth A, Slobedman B.

J Virol. 2015 Jan 15;89(2):1479-83. doi: 10.1128/JVI.02988-14. Epub 2014 Nov 12.

15.

HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells.

Stanton RJ, Prod'homme V, Purbhoo MA, Moore M, Aicheler RJ, Heinzmann M, Bailer SM, Haas J, Antrobus R, Weekes MP, Lehner PJ, Vojtesek B, Miners KL, Man S, Wilkie GS, Davison AJ, Wang ECY, Tomasec P, Wilkinson GWG.

Cell Host Microbe. 2014 Aug 13;16(2):201-214. doi: 10.1016/j.chom.2014.07.005.

16.

[Ananlysis of phosphoproteins and signalling pathways by quantitative proteomics].

Pjechová M, Hernychova L, Tomašec P, Wilkinson GW, Vojtěšek B.

Klin Onkol. 2014;27 Suppl 1:S116-20. Review. Czech.

PMID:
24945548
17.

Quantitative temporal viromics: an approach to investigate host-pathogen interaction.

Weekes MP, Tomasec P, Huttlin EL, Fielding CA, Nusinow D, Stanton RJ, Wang EC, Aicheler R, Murrell I, Wilkinson GW, Lehner PJ, Gygi SP.

Cell. 2014 Jun 5;157(6):1460-72. doi: 10.1016/j.cell.2014.04.028.

18.

HPV integration detection in CaSki and SiHa using detection of integrated papillomavirus sequences and restriction-site PCR.

Raybould R, Fiander A, Wilkinson GW, Hibbitts S.

J Virol Methods. 2014 Sep;206:51-4. doi: 10.1016/j.jviromet.2014.05.017. Epub 2014 May 29.

PMID:
24880069
19.

Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.

Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S, Davies J, McSharry BP, Weekes MP, Antrobus PR, Prod'homme V, Blanchet FP, Sugrue D, Cuff S, Roberts D, Davison AJ, Lehner PJ, Wilkinson GW, Tomasec P.

PLoS Pathog. 2014 May 1;10(5):e1004058. doi: 10.1371/journal.ppat.1004058. eCollection 2014 May.

20.

Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV.

Stacey MA, Marsden M, Pham N TA, Clare S, Dolton G, Stack G, Jones E, Klenerman P, Gallimore AM, Taylor PR, Snelgrove RJ, Lawley TD, Dougan G, Benedict CA, Jones SA, Wilkinson GW, Humphreys IR.

Cell Host Microbe. 2014 Apr 9;15(4):471-83. doi: 10.1016/j.chom.2014.03.003.

21.

Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.

Holcakova J, Muller P, Tomasec P, Hrstka R, Nekulova M, Krystof V, Strnad M, Wilkinson GW, Vojtesek B.

PLoS One. 2014 Feb 21;9(2):e89228. doi: 10.1371/journal.pone.0089228. eCollection 2014.

22.

Human cytomegalovirus suppresses Fas expression and function.

Seirafian S, Prod'homme V, Sugrue D, Davies J, Fielding C, Tomasec P, Wilkinson GW.

J Gen Virol. 2014 Apr;95(Pt 4):933-9. doi: 10.1099/vir.0.058313-0. Epub 2014 Jan 6.

23.

Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation.

Clark SR, Thomas CP, Hammond VJ, Aldrovandi M, Wilkinson GW, Hart KW, Murphy RC, Collins PW, O'Donnell VB.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5875-80. doi: 10.1073/pnas.1222419110. Epub 2013 Mar 25.

24.

Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemčovičová I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA.

Cell Host Microbe. 2013 Mar 13;13(3):324-35. doi: 10.1016/j.chom.2013.02.003.

25.

Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18.

Prod'homme V, Tomasec P, Cunningham C, Lemberg MK, Stanton RJ, McSharry BP, Wang EC, Cuff S, Martoglio B, Davison AJ, Braud VM, Wilkinson GW.

J Immunol. 2012 Mar 15;188(6):2794-804. doi: 10.4049/jimmunol.1102068. Epub 2012 Feb 15.

26.

High-resolution human cytomegalovirus transcriptome.

Gatherer D, Seirafian S, Cunningham C, Holton M, Dargan DJ, Baluchova K, Hector RD, Galbraith J, Herzyk P, Wilkinson GW, Davison AJ.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19755-60. doi: 10.1073/pnas.1115861108. Epub 2011 Nov 22.

27.

Winning policy change to promote community health workers: lessons from massachusetts in the health reform era.

Mason T, Wilkinson GW, Nannini A, Martin CM, Fox DJ, Hirsch G.

Am J Public Health. 2011 Dec;101(12):2211-6. doi: 10.2105/AJPH.2011.300402. Epub 2011 Oct 20.

28.

IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection.

Stacey MA, Marsden M, Wang EC, Wilkinson GW, Humphreys IR.

J Immunol. 2011 Sep 15;187(6):2944-52. doi: 10.4049/jimmunol.1101021. Epub 2011 Aug 17.

29.

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW.

J Clin Invest. 2010 Sep;120(9):3191-208. doi: 10.1172/JCI42955. Epub 2010 Aug 2.

30.

Differential relocation and stability of PML-body components during productive human cytomegalovirus infection: detailed characterization by live-cell imaging.

Dimitropoulou P, Caswell R, McSharry BP, Greaves RF, Spandidos DA, Wilkinson GW, Sourvinos G.

Eur J Cell Biol. 2010 Oct;89(10):757-68. doi: 10.1016/j.ejcb.2010.05.006.

PMID:
20599291
31.

Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture.

Dargan DJ, Douglas E, Cunningham C, Jamieson F, Stanton RJ, Baluchova K, McSharry BP, Tomasec P, Emery VC, Percivalle E, Sarasini A, Gerna G, Wilkinson GW, Davison AJ.

J Gen Virol. 2010 Jun;91(Pt 6):1535-46. doi: 10.1099/vir.0.018994-0.

32.

The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro.

McLaren JE, Calder CJ, McSharry BP, Sexton K, Salter RC, Singh NN, Wilkinson GW, Wang EC, Ramji DP.

J Immunol. 2010 May 15;184(10):5827-34. doi: 10.4049/jimmunol.0903782. Epub 2010 Apr 21.

33.

Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112.

Prod'homme V, Sugrue DM, Stanton RJ, Nomoto A, Davies J, Rickards CR, Cochrane D, Moore M, Wilkinson GW, Tomasec P.

J Gen Virol. 2010 Aug;91(Pt 8):2034-9. doi: 10.1099/vir.0.021931-0. Epub 2010 Apr 21.

34.

The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B.

Antivir Chem Chemother. 2010 Jan 5;20(3):133-42. doi: 10.3851/IMP1460.

35.

Jenner's irony: cowpox taps into T cell evasion.

Wilkinson GW, Lehner PJ.

Cell Host Microbe. 2009 Nov 19;6(5):395-7. doi: 10.1016/j.chom.2009.11.001.

36.

Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens.

Cunningham C, Gatherer D, Hilfrich B, Baluchova K, Dargan DJ, Thomson M, Griffiths PD, Wilkinson GW, Schulz TF, Davison AJ.

J Gen Virol. 2010 Mar;91(Pt 3):605-15. doi: 10.1099/vir.0.015891-0. Epub 2009 Nov 11.

37.

High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169.

Bradley AJ, Lurain NS, Ghazal P, Trivedi U, Cunningham C, Baluchova K, Gatherer D, Wilkinson GW, Dargan DJ, Davison AJ.

J Gen Virol. 2009 Oct;90(Pt 10):2375-80. doi: 10.1099/vir.0.013250-0. Epub 2009 Jun 24.

38.

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.

Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW.

Biotechniques. 2008 Dec;45(6):659-62, 664-8.

39.

Genotypic analysis of two hypervariable human cytomegalovirus genes.

Bradley AJ, Kovács IJ, Gatherer D, Dargan DJ, Alkharsah KR, Chan PK, Carman WF, Dedicoat M, Emery VC, Geddes CC, Gerna G, Ben-Ismaeil B, Kaye S, McGregor A, Moss PA, Pusztai R, Rawlinson WD, Scott GM, Wilkinson GW, Schulz TF, Davison AJ.

J Med Virol. 2008 Sep;80(9):1615-23. doi: 10.1002/jmv.21241.

40.

Differential requirements of the C terminus of Nbs1 in suppressing adenovirus DNA replication and promoting concatemer formation.

Lakdawala SS, Schwartz RA, Ferenchak K, Carson CT, McSharry BP, Wilkinson GW, Weitzman MD.

J Virol. 2008 Sep;82(17):8362-72. doi: 10.1128/JVI.00900-08. Epub 2008 Jun 18.

41.

Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.

McSharry BP, Burgert HG, Owen DP, Stanton RJ, Prod'homme V, Sester M, Koebernick K, Groh V, Spies T, Cox S, Little AM, Wang EC, Tomasec P, Wilkinson GW.

J Virol. 2008 May;82(9):4585-94. doi: 10.1128/JVI.02251-07. Epub 2008 Feb 20.

42.

Modulation of natural killer cells by human cytomegalovirus.

Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R, McSharry BP, Rickards CR, Cochrane D, Llewellyn-Lacey S, Wang EC, Griffin CA, Davison AJ.

J Clin Virol. 2008 Mar;41(3):206-12. Review.

43.

Therapeutic vaccines for cervical cancer: concept and clinical results.

Fiander A, Man S, Borysiewicz LK, Wilkinson GW.

BioDrugs. 1997 Nov;8(5):331-8.

PMID:
18020523
44.

Review of the 6th national meeting of the Italian Society of Virology, a joint meeting with Virus Group of the Society for General Microbiology (UK).

Salata C, Calistri A, Wilkinson GW, Palù G.

J Cell Physiol. 2007 Dec;213(3):844-7. No abstract available.

PMID:
17541933
45.

Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death.

Reeves MB, Davies AA, McSharry BP, Wilkinson GW, Sinclair JH.

Science. 2007 Jun 1;316(5829):1345-8.

46.

Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression.

Stanton RJ, McSharry BP, Rickards CR, Wang EC, Tomasec P, Wilkinson GW.

J Virol. 2007 Aug;81(15):7860-72. Epub 2007 May 23.

47.

Adenovirus vector delivery stimulates natural killer cell recognition.

Tomasec P, Wang EC, Groh V, Spies T, McSharry BP, Aicheler RJ, Stanton RJ, Wilkinson GW.

J Gen Virol. 2007 Apr;88(Pt 4):1103-8.

48.

The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.

Prod'homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, López-Botet M, Wilkinson GW, Tomasec P.

J Immunol. 2007 Apr 1;178(7):4473-81.

49.

Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis.

Wills MR, Ashiru O, Reeves MB, Okecha G, Trowsdale J, Tomasec P, Wilkinson GW, Sinclair J, Sissons JG.

J Immunol. 2005 Dec 1;175(11):7457-65.

50.

A high-efficiency system of natural killer cell cloning.

Morris RJ, Chong LK, Wilkinson GW, Wang EC.

J Immunol Methods. 2005 Dec 20;307(1-2):24-33. Epub 2005 Oct 21.

Supplemental Content

Loading ...
Support Center